Presently, two ongoing clinical trials (NCT04321096 & NCT04338906) are testing the efficacy of TMPRSS2 inhibition by camostat mesilate to evaluate its benefits against COVID-19. This evidence concerns the gene TMPRSS2 and COVID-19.